<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="51349">Polyamine</z:chebi>-<z:chebi fb="0" ids="27418">naphthoquinone</z:chebi> conjugates 5a-c were synthesized by nucleophilic displacement of 2-<z:chebi fb="8" ids="32772">methoxy</z:chebi>-<z:chebi fb="0" ids="44401">lawsone</z:chebi> 3a, 2-methoxylapachol 3b and 2-<z:chebi fb="8" ids="32772">methoxy</z:chebi>-nor-lapachol 3c with the <z:chebi fb="0" ids="51349">polyamine</z:chebi> N1-<z:chebi fb="1" ids="48502">Boc</z:chebi>-N5-Bn-<z:chebi fb="0" ids="16610">spermidine</z:chebi> 4 </plain></SENT>
<SENT sid="1" pm="."><plain>Unprotected derivatives 6a-c were synthesized to evaluate the effect of the protective <z:chebi fb="0" ids="48502">Boc group</z:chebi> on the activity of compounds 5a-c </plain></SENT>
<SENT sid="2" pm="."><plain>The colorimetric <z:chebi fb="0" ids="53233">MTT</z:chebi> assay was used to evaluate their cytotoxic activity </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> compounds were active against human lines of promyelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60), <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> (GLC4), Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (Daudi) and a mouse <z:e sem="disease" ids="C1458155" disease_type="Neoplastic Process" abbrv="">breast tumor</z:e> (Ehrlich <z:mp ids='MP_0002038'>carcinoma</z:mp>), but only unprotected 6a-c showed activity against the human line of <z:hpo ids='HP_0002861'>melanoma</z:hpo> (MV-3) </plain></SENT>
<SENT sid="4" pm="."><plain>IC50 values were obtained from dose response curves by linear regression </plain></SENT>
<SENT sid="5" pm="."><plain>DNA fragmentation was measured by quantification of the subG1 peak of the cell cycle </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60 treated with 5c was dose-dependent </plain></SENT>
<SENT sid="7" pm="."><plain>The amount of DNA fragmentation observed by exposure of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60 to 25 microM of compounds 5a-c and 6a-c is compatible with the decrease in viability induced by the drugs at this concentration </plain></SENT>
<SENT sid="8" pm="."><plain>Production of ROS was measured by H2-CFDA </plain></SENT>
<SENT sid="9" pm="."><plain>Kinetics of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60 DNA fragmentation and ROS formation by 5c indicated that production of ROS precedes cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, <z:chebi fb="0" ids="16610">spermidine</z:chebi>-1,4-<z:chebi fb="0" ids="27418">naphthoquinone</z:chebi> conjugates exhibited an increase in activity compared with the <z:chebi fb="15" ids="33243">natural products</z:chebi> and induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines by a mechanism that is mediated, at least in part, by ROS production </plain></SENT>
</text></document>